Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma

被引：3

作者：

Ribas, C

Colleoni, G

Almeida, M

Duch, CR

Ohashi, C

Segreto, R

Silva, MR

机构：

[1] Univ Fed Sao Paulo, EPM, Dept Hematol & Hemotherapy, Sao Paulo, Brazil

[2] Univ Fed Sao Paulo, EPM, Dept Radiotherapy, Sao Paulo, Brazil

[3] Univ Fed Sao Paulo, EPM, Dept Pathol, Sao Paulo, Brazil

来源：

ACTA ONCOLOGICA | 2004年 / 43卷 / 02期

关键词：

D O I：

10.1080/02841860310021536

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：215 / 216

页数：2

共 6 条

[1] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[2] Thalidomide in multiple myeloma:: lack of response of soft-tissue plasmacytomas [J].

Bladé, J ;

Perales, M ;

Rosiñol, L ;

Tuset, M ;

Montoto, S ;

Esteve, O ;

Cobo, F ;

Villela, L ;

Rafel, M ;

Nomdedeu, B ;

Montserrat, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :422-424

[3] Solitary plasmacytoma of bone and extramedullary plasmacytoma [J].

Dimopoulos, MA ;

Kiamouris, C ;

Moulopoulos, LA .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (06) :1249-+

[4] Low-dose thalidomide in myeloma: Efficacy and biologic significance [J].

Durie, BGM .

SEMINARS IN ONCOLOGY, 2002, 29 (06) :34-38

[5] Prognostic value of angiogenesis in solitary bone plasmacytoma [J].

Kumar, S ;

Fonseca, R ;

Dispenzieri, A ;

Lacy, MQ ;

Lust, JA ;

Wellik, L ;

Witzig, TE ;

Gertz, MA ;

Kyle, RA ;

Greipp, PR ;

Rajkumar, SV .

BLOOD, 2003, 101 (05) :1715-1717

[6]

Wechalekar AD, 2001, BLOOD, V98, p162A

← 1 →